Blood Calcium Levels Linked to Ovarian Cancer
By LabMedica International staff writers Posted on 13 Feb 2013 |
High blood calcium levels might predict ovarian cancer, the most fatal of the gynecological cancers.
Many ovarian cancers express parathyroid hormone-related protein, which acts to raise calcium levels in serum, which may be a biomarker for ovarian cancer.
Cancer epidemiologists at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) measured total and ionized serum calcium levels using ion-specific electrodes. They were pH-adjusted because the protein binding of calcium is affected by pH; ionized calcium in blood is commonly corrected to standard pH. Serum samples were collected as part of Third National Health and Nutrition Examination Surveys (NHANES III) between 1988 and 1994 from two nationally representative prospective cohorts.
Eleven ovarian cancer deaths were observed over 95,556 person-years of follow-up through December 31, 2006, representing 137,404 ovarian cancer deaths in the United States of America. The range in total serum calcium in cases was 2.14–2.44 mmol/L and for ionized serum calcium was 1.17–1.31 mmol/L. The normal reference range for total serum calcium is approximately 2.17–2.52 mmol/L and 1.12–1.32 mmol/L for ionized serum calcium. In the second cohort, there were eight ovarian cancer cases in over 31,089 person-years of follow-up. The range of total serum calcium was 1.98–2.93 mmol/L. The relative hazard for fatal ovarian cancer was 1.52 per 0.1 mmol/L increase in total serum calcium and 2.44 per 0.1 mmol/L increase in ionized serum calcium.
Gary G. Schwartz, PhD, the lead author of the study, said "One approach to cancer biomarker discovery is to identify a factor that is differentially expressed in individuals with and without cancer and to examine that factor's ability to detect cancer in an independent sample of individuals." His coauthor added, "Everyone's got calcium and the body regulates it very tightly. We know that some rare forms of ovarian cancer are associated with very high calcium, so it's worth considering whether more common ovarian cancers are associated with moderately high calcium."
The authors concluded that this biomarker, the higher levels of calcium in serum, were significantly positively associated with the risk of ovarian cancer in two prospective cohorts. The principal limitation of this study is the small number of cases. Conversely, the study has several strengths: it is prospective, uses population-based data from two nationally representative cohorts, and is the first to study ionized serum calcium. The existence of stored sera from sample sets of women with and without ovarian cancer should facilitate the confirmation or refutation of the association between serum calcium and ovarian cancer. The study was published January 9, 2013, in the journal Gynecologic Oncology.
Related Links:
Wake Forest Baptist Medical Center
Many ovarian cancers express parathyroid hormone-related protein, which acts to raise calcium levels in serum, which may be a biomarker for ovarian cancer.
Cancer epidemiologists at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) measured total and ionized serum calcium levels using ion-specific electrodes. They were pH-adjusted because the protein binding of calcium is affected by pH; ionized calcium in blood is commonly corrected to standard pH. Serum samples were collected as part of Third National Health and Nutrition Examination Surveys (NHANES III) between 1988 and 1994 from two nationally representative prospective cohorts.
Eleven ovarian cancer deaths were observed over 95,556 person-years of follow-up through December 31, 2006, representing 137,404 ovarian cancer deaths in the United States of America. The range in total serum calcium in cases was 2.14–2.44 mmol/L and for ionized serum calcium was 1.17–1.31 mmol/L. The normal reference range for total serum calcium is approximately 2.17–2.52 mmol/L and 1.12–1.32 mmol/L for ionized serum calcium. In the second cohort, there were eight ovarian cancer cases in over 31,089 person-years of follow-up. The range of total serum calcium was 1.98–2.93 mmol/L. The relative hazard for fatal ovarian cancer was 1.52 per 0.1 mmol/L increase in total serum calcium and 2.44 per 0.1 mmol/L increase in ionized serum calcium.
Gary G. Schwartz, PhD, the lead author of the study, said "One approach to cancer biomarker discovery is to identify a factor that is differentially expressed in individuals with and without cancer and to examine that factor's ability to detect cancer in an independent sample of individuals." His coauthor added, "Everyone's got calcium and the body regulates it very tightly. We know that some rare forms of ovarian cancer are associated with very high calcium, so it's worth considering whether more common ovarian cancers are associated with moderately high calcium."
The authors concluded that this biomarker, the higher levels of calcium in serum, were significantly positively associated with the risk of ovarian cancer in two prospective cohorts. The principal limitation of this study is the small number of cases. Conversely, the study has several strengths: it is prospective, uses population-based data from two nationally representative cohorts, and is the first to study ionized serum calcium. The existence of stored sera from sample sets of women with and without ovarian cancer should facilitate the confirmation or refutation of the association between serum calcium and ovarian cancer. The study was published January 9, 2013, in the journal Gynecologic Oncology.
Related Links:
Wake Forest Baptist Medical Center
Latest Clinical Chem. News
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Channels
Molecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more